Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 144-151 , May 2010

Should we use apoB for risk assessment and as a target for treatment?†

  • W. Virgil Brown, MD

      Affiliations

    • Editor-in-Chief, The Journal of Clinical Lipidology, Charles Howard Candler Professor of Internal Medicine Emeritus, Emory University School of Medicine, 1670 Clairmont Road, Atlanta, GA 30033
    • Corresponding Author InformationCorresponding author.
    • ,
  • Gary L. Myers, PhD

      Affiliations

    • Chief of the Clinical Chemistry Branch at the Centers for Disease Control and Prevention (CDC), Atlanta, GA
    • ,
  • Allan D. Sniderman, MD

      Affiliations

    • Edwards Professor of Cardiology, Professor of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
    • ,
  • Evan Stein, MD, PhD

      Affiliations

    • Director of the Metabolic and Atherosclerosis Research Center, Cincinnati, OH

Received 5 March 2010 ,Accepted 5 March 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1933-2874(10)00103-0

doi: 10.1016/j.jacl.2010.03.004

Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 144-151 , May 2010

Article Tools

* Image Usage & Resolution